Phase 2 Evidence and Impact Analysis
Article 1 — Sequential diagnosis with language models (PMID 42912144)
Study Design: Benchmark study | Journal: Science | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | First demonstration of a frontier LLM physician-panel simulator achieving >80% diagnostic accuracy on two independent real-world benchmarks, substantially exceeding generalist physicians |
| Clinical Relevance | 8 | Directly informs clinical AI decision-support design; benchmark results are compelling, but this is not yet a deployed clinical tool — prospective validation in live care settings is the critical next step |
| Population Reach | 9 | Diagnostic reasoning applies across all clinical specialties and geographies; global implications for healthcare systems with physician shortages |
| Implementation Speed | 6 | LLM infrastructure exists; regulatory clearance, liability frameworks, EHR integration, and clinical workflow adoption are non-trivial hurdles |
| Evidence Strength | 7 | High-quality benchmark on two independent datasets (NEJM CPC + MIMIC-IV); peer-reviewed in Science; limitation is that benchmarks do not equal real-world prospective performance |
Key Quantitative Result: 83.2% diagnostic accuracy (NEJM CPC); 80.3% (MIMIC-IV ED) vs. 36.1%/46.8% for generalist physicians — a ~2× improvement.
External Validation: Validated on two independent datasets; no prospective clinical trial yet.
Main Limitation: Benchmark performance does not capture real-world complexity: dynamic patient interaction, missing data, EHR noise, clinical liability, and human-AI communication failures in live settings.
Equity Implications: Potentially large benefit for underserved populations lacking specialist access; however, English-language/Western EHR training data may underperform in non-Western, low-resource, or multilingual settings. Deployment infrastructure costs could widen the gap.
Evidence Maturity (confirmed): Validated (benchmark-level) — not yet Potentially Practice-Changing without prospective trials.
Article 2 — Ravulizumab in IgA Nephropathy (PMID 42912700)
Study Design: Phase 3 RCT (interim analysis) | Journal: NEJM | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First Phase 3 evidence for complement C5 inhibition in IgA nephropathy; mechanistically distinct from existing sparsentan/SGLT2i approaches |
| Clinical Relevance | 9 | Directly addresses a progressive, incurable kidney disease in adults; 43.4% greater proteinuria reduction with favorable safety is clinically meaningful and likely to influence guideline consideration |
| Population Reach | 6 | IgAN affects ~1.3 million people globally, the most common primary glomerulonephritis, but it is still a rare disease; scored 6 relative to rare disease unmet need context (high within category) |
| Implementation Speed | 7 | Phase 3 interim data; ravulizumab already FDA-approved for PNH/aHUS — regulatory pathway likely faster than de novo agents; IV every 8 weeks is manageable |
| Evidence Strength | 8 | Phase 3 RCT in NEJM; only interim analysis, so long-term renal survival data pending; meningococcal vaccination requirement adds safety management complexity |
Key Quantitative Result: 43.4% greater reduction in 24-hour uPCR vs. placebo at Week 34 (P<0.001); serious adverse events 4.6% vs. 9.0%.
External Validation: This IS the pivotal trial; no independent replication yet, but interim analysis from a well-powered Phase 3 RCT.
Main Limitation: Interim analysis only — primary endpoint of eGFR slope protection over longer follow-up not yet reported; interim proteinuria data may not fully predict hard renal outcomes.
Equity Implications: Ravulizumab will likely be expensive (cf. eculizumab ~$400K–700K/year); patients in low- and middle-income countries where IgAN is highly prevalent (East Asia) may have very limited access. Biosimilar development and health system negotiations will determine equity of access.
Evidence Maturity (confirmed): Potentially Practice-Changing — pending full trial completion and regulatory review.
Article 3 — CAR T-cell exhaustion mitigated by non-alpha IL2R agonist (PMID 42913488)
Study Design: Preclinical (scRNA-seq, in vitro, patient-derived in vivo model) | Journal: Blood | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Mechanistically precise identification of reduced IL2 signaling as the driver of CART19 exhaustion with single-cell resolution; pegenzileukin rescuing CNS relapse in a patient-derived model is highly novel |
| Clinical Relevance | 5 | Preclinical only — cannot exceed 5; however, pegenzileukin is a clinically available/investigated agent, and the patient-derived model adds translational credibility |
| Population Reach | 7 | CART19 failure affects a significant fraction of relapsed/refractory B-cell lymphoma patients — a population with no good salvage options; high unmet need |
| Implementation Speed | 4 | Preclinical stage; clinical combination trial design is the immediate next step, but regulatory, manufacturing, and safety data for the combination are needed; 5–10 year horizon |
| Evidence Strength | 5 | Rigorous mechanistic design (scRNA-seq + in vitro + PDX); but strictly preclinical, non-human/animal models — cannot exceed 5 on Clinical Relevance per scoring rules; limited by absence of human clinical data |
Key Quantitative Result: Complete tumor eradication including CNS clearance in patient-derived in vivo model with pegenzileukin; CART19 exhaustion reversed in vitro.
External Validation: No independent replication; single-institution preclinical study from MD Anderson.
Main Limitation: No human clinical data; patient-derived xenograft models do not fully recapitulate immune microenvironment or toxicity in immunocompetent humans; pegenzileukin clinical safety in this combination is unknown.
Equity Implications: If combination therapy succeeds clinically, CART19 therapy access disparities (specialized centers, high cost) would amplify inequity — underserved patients already have reduced access to CAR-T programs.
Evidence Maturity (revised): Exploratory — confirmed. Despite high novelty, strictly preclinical.
Article 4 — CD123×Vdelta2 bispecific T-cell engager in AML/MDS (PMID 42918561)
Study Design: Preclinical (in vitro + xenograft + NHP PK); Phase 1 initiated | Journal: Clin Immunol | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Novel gamma-delta T-cell redirecting mechanism for AML/MDS; lower CRS profile vs CD3-based bispecifics is a meaningful innovation; NHP PK validates antibody-like half-life |
| Clinical Relevance | 4 | Preclinical — capped at 5; Phase 1 initiation is encouraging but no clinical efficacy or safety data yet |
| Population Reach | 7 | AML/MDS together represent ~30,000 new cases/year in the US; high unmet need in relapsed/refractory setting |
| Implementation Speed | 5 | Phase 1 already registered; if safety is favorable, Phase 2 results could emerge in 3–5 years; manufacturing of bispecifics is established |
| Evidence Strength | 5 | Comprehensive preclinical package (patient-derived cells, xenograft, NHP PK); Phase 1 initiation is a credibility signal; no human efficacy data |
Key Quantitative Result: Potent selective lysis of patient-derived AML/MDS cells; lower CRS cytokines vs CD3-based bispecifics in vitro; antibody-like PK in NHP; Phase 1 ACTRN12624001214527 initiated.
External Validation: No independent replication; single-team preclinical data.
Main Limitation: No human clinical data; xenograft models cannot fully predict CRS in humans; gamma-delta T-cell availability and expansion could be patient-variable.
Equity Implications: AML/MDS disproportionately affects older adults; if approved, access to bispecific therapies at specialized centers could limit equity for rural/low-income patients.
Evidence Maturity (confirmed): Exploratory.
Article 5 — AI reliance patterns in medical imaging (PMID 42919730)
Study Design: Randomized crossover experiment (preregistered) | Journal: Lancet Digital Health | Triage Score: 9
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Quantifies under- vs. over-reliance risk in AI-assisted radiology with preregistered design; explainable AI superiority over basic AI output is novel in this rigorous format |
| Clinical Relevance | 8 | Directly actionable for AI deployment guidelines, training programs, and UI design in clinical radiology — findings are implementable now |
| Population Reach | 8 | Medical imaging AI is being deployed globally; findings apply to any clinical setting using AI-assisted image interpretation |
| Implementation Speed | 8 | No new technology required — findings inform how existing AI tools should be deployed and presented; guideline and UX changes can happen rapidly |
| Evidence Strength | 8 | Preregistered RCT, 125 clinicians, crossover design minimizing confounding; limitation is single imaging modality (head CT) and artificial experimental setting |
Key Quantitative Result: Explainable AI improved diagnostic performance vs. no advice (OR=1.84, P<0.0001); under-reliance on correct AI was the dominant failure mode.
External Validation: Preregistration adds credibility; generalizability to other modalities/AI systems not yet tested.
Main Limitation: Single modality (head CT); simulated clinical setting may not fully capture real-world time pressure, case volume, and multi-tasking effects.
Equity Implications: Under-reliance risk may differ across training backgrounds and resource settings — clinicians with less radiology training may behave differently. Explainable AI requires additional development cost that may not reach lower-resource settings.
Evidence Maturity (confirmed): Potentially Practice-Changing.
Article 6 — Gut virome remodeling after FMT in obesity/T2D (PMID 42912803)
Study Design: RCT mechanistic virome sub-study | Journal: Gut Microbes | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First RCT-embedded mechanistic data showing gut virome remodeling predicts metabolic outcomes in FMT for T2D/obesity; Caudoviricetes phages as metabolic mediators is a genuinely new concept |
| Clinical Relevance | 6 | Mechanistic insight, not yet actionable for treatment selection; virome-informed FMT optimization is a future possibility but not yet translatable to practice |
| Population Reach | 9 | Obesity and T2D affect >1 billion people globally; any insight into optimizing FMT or microbiome-targeted therapy has enormous population relevance |
| Implementation Speed | 4 | Virome profiling is not yet clinical-grade; FMT for metabolic disease is not yet standard of care; 5–10 year horizon for clinical translation |
| Evidence Strength | 7 | RCT-derived mechanistic sub-study is a significant strength; machine learning prediction model (AUC 0.848) is robust; limitation is small N and single-center |
Key Quantitative Result: Donor viral engraftment in 58.8–64.7% of FMT recipients vs. 5.6% sham; virome predicted LDL response with 84.8% accuracy vs. bacteriome 81.4%.
External Validation: Sub-study of an existing RCT; no independent replication yet.
Main Limitation: Small sample size; single-center; causal role of virome vs. bacteriome co-variation not established.
Equity Implications: FMT for metabolic disease is not widely available; clinical virome profiling would add cost and complexity, likely first accessible in high-income settings.
Evidence Maturity (confirmed): Potentially Practice-Changing (mechanistic foundation; not yet practice-changing in implementation).
Article 7 — mChIP-seq for multiplex epigenomic cancer detection (PMID 42913642)
Study Design: Methods development / proof-of-concept | Journal: Cell Reports Methods | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Simultaneous profiling of 11 histone modifications and extension to cell-free plasma nucleosomes is technically novel; multi-mark liquid biopsy approach exceeds current single-mark platforms |
| Clinical Relevance | 5 | Proof-of-concept in breast cancer cell lines and limited plasma samples; not yet a clinical test |
| Population Reach | 8 | Breast cancer is the most common cancer in women; pan-cancer potential adds broad relevance |
| Implementation Speed | 3 | Technology requires substantial clinical validation, standardization, regulatory clearance, and cost reduction; 7–10+ year horizon |
| Evidence Strength | 6 | Technically rigorous methods paper; full-text access; limitation is proof-of-concept scale — small number of patient samples |
Key Quantitative Result: Multiplex H2A.Z, H3K4me3, H3K27ac, H3K9me3 profiling in circulating nucleosomes distinguished breast cancer from healthy controls; reduced H2A.Z-H3K4me3 correlation is a novel cancer-specific signature.
External Validation: No independent replication; single-institution methods paper.
Main Limitation: Small proof-of-concept sample; no performance metrics (sensitivity/specificity) reported at clinical scale; cancer type specificity not yet established.
Equity Implications: Liquid biopsy approaches hold promise for equalizing access vs. tissue biopsy, but only if costs are eventually reduced to accessible levels.
Evidence Maturity (revised): Exploratory → Validated (methods-level); "Validated" in the triage may overstate clinical readiness. Reclassified as Exploratory for clinical translation purposes.
Article 8 — Perioperative nivolumab in MIBC — CA017-078 final results (PMID 42918420)
Study Design: Phase 3 RCT (final analysis) | Journal: Annals of Oncology | Triage Score: 8
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Important null finding on EFS despite improved pCR; ctDNA prognostic data in MIBC adds genuine novelty |
| Clinical Relevance | 8 | Final Phase 3 data directly informs standard-of-care decisions for muscle-invasive bladder cancer; the pCR/EFS disconnect has immediate practice implications |
| Population Reach | 7 | ~80,000 new bladder cancer cases/year in the US; MIBC represents a significant fraction with major unmet need |
| Implementation Speed | 8 | Results are immediately usable for clinical decision-making and trial design; ctDNA findings could shift biomarker strategy now |
| Evidence Strength | 8 | Well-powered Phase 3 RCT with final analysis; 54.5-month follow-up; limitation is that null result on EFS may reflect inadequate statistical power or wrong patient selection |
Key Quantitative Result: pCR 39.1% vs. 29.6% (improved); EFS HR 0.94, P=0.67 (no benefit); ctDNA positivity strongly prognostic for EFS and OS.
External Validation: This is the pivotal trial; no independent replication, but the null EFS result is internally consistent and credible.
Main Limitation: Negative primary endpoint; pCR surrogate may not translate to survival benefit in this setting; ctDNA findings are exploratory.
Equity Implications: Bladder cancer has higher incidence in men, White populations, and those with occupational chemical exposures (industrial workers). Immunotherapy access disparities exist by insurance status and geography.
Evidence Maturity (confirmed): Potentially Practice-Changing (negative result that closes one door and redirects to biomarker-selected design).
Article 9 — Frontline BTKi in primary CNS lymphoma (PMID 42913449)
Study Design: Retrospective cohort with IPTW adjustment | Journal: Blood Advances | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | BTKi activity in PCNSL is established; frontline data with IPTW analysis adds evidence but is not groundbreaking |
| Clinical Relevance | 7 | PCNSL is a devastating rare CNS malignancy with no agreed standard; BTKi frontline showing PFS benefit (HR 0.57) and 5.5× higher CR rate is clinically meaningful |
| Population Reach | 4 | PCNSL is rare (~1,500 cases/year in the US); scored within rare disease context |
| Implementation Speed | 7 | BTKi agents (ibrutinib, zanubrutinib) are widely available; treatment change could occur relatively rapidly with RCT confirmation |
| Evidence Strength | 5 | Retrospective; IPTW adjustment mitigates but does not eliminate confounding; n=85; single-center; no blinding |
Key Quantitative Result: PFS HR 0.57 (P=0.048); CR OR 5.50 (P<0.001) with BTKi-based frontline vs. HD-MTX.
External Validation: No independent replication; single-center retrospective.
Main Limitation: Retrospective design; selection bias for BTKi despite IPTW; small n; no OS benefit reported; RCT needed.
Equity Implications: BTKi drugs are expensive and not universally covered; PCNSL patients in lower-income settings may not access these agents.
Evidence Maturity (confirmed): Validated (observational level).
Article 10 — Acute Erythroid Leukemia from myeloid neoplasms (PMID 42918306)
Study Design: Retrospective multi-institutional cohort | Journal: Modern Pathology | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Definitively confirms clonal continuity in AEL (100% concordance); convergent TP53/complex karyotype finding is important but partially anticipated |
| Clinical Relevance | 6 | Clarifies diagnostic classification and prognosis; OS of ~1.4–1.5 months underscores extreme unmet need; limited immediate treatment implications |
| Population Reach | 3 | AEL is extremely rare; scored within rare disease/unmet need context |
| Implementation Speed | 6 | Pathology classification changes can be implemented relatively quickly; prognostic data immediately applicable to counseling |
| Evidence Strength | 7 | Largest AEL cohort to date (n=116); multi-institutional; 100% clonal continuity in 58 longitudinal cases is a robust finding |
Key Quantitative Result: 100% clonal continuity between precursor MN and AEL (n=58); median OS ~1.4–1.5 months.
External Validation: Multi-institutional design provides some internal validation; independent cohort replication not yet available.
Main Limitation: Retrospective; treatment heterogeneity across institutions; limited molecular depth.
Equity Implications: Rare leukemia disproportionately affects older adults; the dismal OS reflects lack of effective treatment — not yet an equity-addressable gap until novel therapies emerge.
Evidence Maturity (confirmed): Validated.
Article 11 — Nivolumab + relatlimab in NSCLC — RELATIVITY-104 (PMID 42918419)
Study Design: Phase 2 RCT | Journal: Annals of Oncology | Triage Score: 7
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | LAG-3+PD-1 dual blockade in NSCLC is an active area; null primary endpoint but PD-L1≥1% nonsquamous OS signal is hypothesis-generating |
| Clinical Relevance | 6 | Negative primary endpoint limits immediate practice change; subgroup signal supports Phase 3 design and biomarker-selected strategy |
| Population Reach | 8 | NSCLC is the leading cause of cancer death globally; any effective new regimen has enormous reach |
| Implementation Speed | 5 | Requires Phase 3 confirmation; relatlimab+nivolumab (Opdualag) already approved in melanoma, so regulatory pathway may be shorter if Phase 3 succeeds |
| Evidence Strength | 6 | Phase 2 RCT; underpowered for subgroup; OS HR 0.60 in subgroup is encouraging but not confirmatory |
Key Quantitative Result: Primary ORR 51.3% vs. 45.0% (not significant); PD-L1≥1% nonsquamous subgroup ORR 58.0% vs. 39.6%; OS HR 0.60.
External Validation: Phase 3 RELATIVITY-1093 ongoing.
Main Limitation: Null primary endpoint; subgroup analysis exploratory only; phase 2 size insufficient for definitive conclusions.
Equity Implications: NSCLC disproportionately affects lower-income populations and heavy smokers; PD-L1 testing availability varies globally.
Evidence Maturity (confirmed): Validated (Phase 2 level).
Article 12 — Capivasertib + abiraterone in PTEN-deficient mHSPC — CAPItello-281 (PMID 42918424)
Study Design: Phase 3 RCT (updated survival analysis) | Journal: Annals of Oncology | Triage Score: 7 | Classification confidence: medium
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | AKT inhibition + abiraterone in PTEN-deficient de novo mHSPC is a precision oncology concept with strong biological rationale; updated survival data adds maturity |
| Clinical Relevance | 6 | PTEN-deficient mHSPC is a poor-prognosis genomically defined subgroup with high unmet need; results depend on effect size not fully captured in abstract-only access |
| Population Reach | 6 | Prostate cancer is common; PTEN-deficient subgroup represents ~30–40% of cases |
| Implementation Speed | 6 | Capivasertib FDA-approved in HR+/HER2- breast cancer (AKTi); PTEN testing is increasingly available; pathway exists |
| Evidence Strength | 6 | Phase 3 RCT updated analysis is high quality; medium classification confidence and abstract-only access limit full scoring |
Key Quantitative Result: Specific survival effect size not captured in available data; evaluates PI3K/AKT inhibition in PTEN-deficient de novo mHSPC.
External Validation: This is the pivotal trial.
Main Limitation: Abstract-only access; medium classification confidence; unknown full efficacy signal from available triage metadata.
Equity Implications: PTEN testing access varies; prostate cancer has racial disparities (higher incidence/mortality in Black men) — targeted therapy access is critical to address.
Evidence Maturity (confirmed): Validated (Phase 3 level, pending full data).
Article 13 — 12-month tirzepatide weight-loss trajectories (PMID 42908672)
Study Design: Retrospective real-world multicenter observational | Journal: Obesity Pillars | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Real-world tirzepatide data is accumulating; 6-month early-response prediction rule (AUC 0.76) is a useful clinical contribution but not novel in mechanism |
| Clinical Relevance | 6 | Early-response prediction rule is immediately actionable for treatment monitoring and dose escalation decisions |
| Population Reach | 9 | Obesity and diabetes affect billions globally; tirzepatide is widely prescribed |
| Implementation Speed | 8 | No new infrastructure required; 6-month check-in rule can be applied immediately |
| Evidence Strength | 5 | Retrospective, self-funded cohort, potential COI (Lilly relationships), Greek-specific prescribing context, no comparator arm |
Key Quantitative Result: 68.3% on-treatment at 12 months; mean 19.9% weight loss; 50% achieved ≥20% loss; 6-month response predicted 12-month ≥20% loss (OR 1.34/percentage point, AUC 0.760).
External Validation: No independent replication of the prediction rule.
Main Limitation: Retrospective; self-funded cohort introduces selection bias; potential COI; Greek practice context may not generalize.
Equity Implications: Self-funded patients are not representative of the general obesity population; those without insurance access are excluded by design.
Evidence Maturity (confirmed): Validated (observational).
Article 14 — ML model for thrombophilia management (PMID 42913722)
Study Design: Retrospective single-center ML model development | Journal: Thrombosis and Haemostasis | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | XGBoost applied to thrombophilia classification is an incremental advance; APS as top feature is biologically expected |
| Clinical Relevance | 5 | Physician concordance 79.6% is reasonable; clinical decision support tool potential but external validation needed |
| Population Reach | 5 | Thrombophilia testing is common but heterogeneous; broad potential if validated externally |
| Implementation Speed | 4 | Single-center; external validation required before deployment |
| Evidence Strength | 4 | Retrospective single-center; n=496; no external validation; test set performance may be optimistic |
Key Quantitative Result: 91.9% macro-averaged sensitivity (adjacent-class accepted); physician concordance 79.6%.
External Validation: None; explicitly noted as a limitation.
Main Limitation: Single-center; no external validation; "adjacent-class" acceptance inflates apparent sensitivity.
Equity Implications: Limited generalizability; thrombophilia management disparities exist across ethnic groups (e.g., factor V Leiden prevalence differences).
Evidence Maturity (confirmed): Validated (internal development only).
Article 15 — Sintilimab + eribulin + carboplatin in metastatic TNBC (PMID 42919625)
Study Design: Phase 2 multicenter trial | Journal: JITC | Triage Score: 6 | Classification confidence: low
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | PD-1 + chemotherapy combinations in TNBC is an established paradigm; specific triplet is incremental |
| Clinical Relevance | 4 | Metastatic TNBC has high unmet need; low confidence and abstract-unavailable severely limit scoring |
| Population Reach | 6 | TNBC represents ~15% of breast cancers; metastatic TNBC has poor prognosis |
| Implementation Speed | 4 | Sintilimab not globally approved (mainly China); Phase 2 only; Phase 3 needed |
| Evidence Strength | 3 | Low classification confidence; abstract/results not available at indexing — scored conservatively per rules |
Key Quantitative Result: Not available from triage metadata.
External Validation: None known.
Main Limitation: Low classification confidence; no extractable results; sintilimab geographic availability limits global applicability.
Equity Implications: TNBC disproportionately affects younger women and those of African ancestry; if effective, access to sintilimab outside China would be a major barrier.
Evidence Maturity (revised): Downgraded to Exploratory pending results access.
Article 16 — DNA nanomachines for ctDNA multiplex detection (PMID 42919761)
Study Design: Methods development / analytical validation | Journal: Science Bulletin | Triage Score: 6
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Molecular filler-enhanced DNA nanomachine architecture enabling amplification-free attomolar detection is technically novel |
| Clinical Relevance | 4 | Analytical performance is strong (AUC 0.96 vs. qPCR); clinical validation in large prospective cohorts is needed |
| Population Reach | 7 | EGFR-mutant NSCLC affects millions globally; ctDNA monitoring has broad oncology application |
| Implementation Speed | 3 | Requires clinical-grade manufacturing, regulatory clearance, and prospective validation; 7–10 year horizon |
| Evidence Strength | 5 | Strong analytical methodology; small NSCLC cohort for clinical claims; no prospective validation |
Key Quantitative Result: LOD 5.2 and 6.0 amol/L for EGFR L858R and T790M; AUC 0.96 vs. qPCR.
External Validation: None; single-institution methods paper.
Main Limitation: Small clinical cohort; no prospective clinical validation; manufacturing scalability unknown.
Equity Implications: Low-cost amplification-free ctDNA testing could eventually improve access in resource-limited settings, but only after clinical validation.
Evidence Maturity (confirmed): Validated (analytical methods level); Exploratory for clinical application.
Article 17 — Del6p and allo-HCT relapse risk (PMID 42913459)
Study Design: Registry analysis | Journal: Blood Advances | Triage Score: 5
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Del6p as an HLA-mediated GVL attenuation mechanism is a biologically coherent and underappreciated hypothesis |
| Clinical Relevance | 5 | Identifies a novel cytogenetic risk factor for relapse post-allo-HCT; could influence donor selection and conditioning strategy |
| Population Reach | 4 | Applies specifically to allo-HCT patients with del6p; niche but important |
| Implementation Speed | 5 | Registry finding could be incorporated into pre-transplant cytogenetic risk assessment relatively quickly |
| Evidence Strength | 5 | National registry provides sample size; retrospective; HR 1.30 is modest; species/population metadata incomplete |
Key Quantitative Result: Del6p associated with increased relapse risk HR 1.30 (P=0.036), stronger in HLA-mismatched settings.
External Validation: National (Japanese) registry; no international replication.
Main Limitation: Modest effect size; retrospective; registry heterogeneity; mechanistic hypothesis (HLA gene loss) not directly tested.
Equity Implications: Japanese-centric registry; del6p frequency and cytogenetic testing availability vary globally.
Evidence Maturity (confirmed): Validated (observational registry level).
Article 18 — DL malaria parasite identification from blood smears (PMID 42910861)
Study Design: Proof-of-concept deep learning model | Journal: Journal of Applied Microbiology | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | YOLOv8 applied to malaria smear classification is incremental; life-cycle stage classification adds some value |
| Clinical Relevance | 4 | Global health relevance for malaria-endemic regions; but n=35 severely limits credibility |
| Population Reach | 8 | Malaria affects >200 million people annually globally; AI-assisted diagnostics could reach high-burden areas |
| Implementation Speed | 3 | Proof-of-concept only; prospective validation in field conditions required; smartphone/microscope integration needed |
| Evidence Strength | 3 | Very small sample (n=35); same-slide hold-out evaluation overly optimistic; mAP@0.5 of 0.673 is moderate |
Key Quantitative Result: mAP@0.5 = 0.673; 99% accuracy for infected vs. uninfected; F1>0.90 for 8/11 stage classes.
External Validation: No external validation; internal hold-out only.
Main Limitation: n=35; same-slide validation inflates performance estimates; rare stage classes poorly represented.
Equity Implications: Direct global health relevance — malaria disproportionately affects sub-Saharan Africa and South/Southeast Asia; AI diagnostics could reduce expert microscopist dependency.
Evidence Maturity (confirmed): Exploratory.
Article 19 — Arid1a/b knockout causes myeloid transformation in mice (PMID 42918388)
Study Design: Preclinical mouse conditional knockout | Journal: Experimental Hematology | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Paradoxical myeloid leukemia from B-cell-targeted BAF complex deletion is a genuinely surprising and mechanistically important finding |
| Clinical Relevance | 2 | Animal-only study; no human data; cap applies — cannot exceed 5; scored 2 given early-stage |
| Population Reach | 3 | Relevant to B-cell malignancy biology; very early stage |
| Implementation Speed | 2 | Lab-stage mouse study; human relevance not yet established |
| Evidence Strength | 4 | Well-controlled conditional knockout model; mechanistically rigorous; mouse-only; no human correlate data |
Key Quantitative Result: Combined Arid1a/Arid1b deletion causes lethal transplantable myeloid leukemia via MPP3 expansion.
External Validation: No independent replication.
Main Limitation: Mouse-only; CD19-Cre model may not reflect human ARID1A/B mutation contexts in lymphoma.
Equity Implications: Too early for equity assessment.
Evidence Maturity (confirmed): Exploratory.
Article 20 — ICU risk factors in AML allo-HCT (PMID 42918577)
Study Design: Retrospective single-institution cohort | Journal: Transplantation and Cellular Therapy | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | ICU risk factors in allo-HCT are known; HCT-CI, TRM score, HLA-mismatch as predictors are established |
| Clinical Relevance | 5 | Useful for pre-transplant counseling and identifying high-risk patients; large single-institution dataset (n=1,265) adds value |
| Population Reach | 5 | AML/MDS transplant patients; relevant clinical population |
| Implementation Speed | 6 | Findings immediately usable in clinical risk assessment |
| Evidence Strength | 5 | Large n for single-institution; retrospective; 17-year span with changing practice standards |
Key Quantitative Result: ICU admission 9.2% by day +100; 43% 100-day mortality in ICU patients.
External Validation: Single institution; no external validation.
Main Limitation: Single-center; 17-year retrospective with evolving standards of care; no prospective validation of risk prediction tool.
Equity Implications: Allo-HCT access is significantly limited by donor availability and center proximity for minority populations.
Evidence Maturity (confirmed): Validated (observational).
Article 21 — PRS for breast cancer prevention — feasibility protocol (PMID 42919576)
Study Design: Study protocol (feasibility) | Journal: BMJ Open | Triage Score: 4
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | PRS implementation in clinical settings is an active area; this is a protocol paper with no results |
| Clinical Relevance | 3 | Protocol only; no results to evaluate; potential future relevance |
| Population Reach | 7 | Breast cancer is the most common cancer in women globally |
| Implementation Speed | 3 | Feasibility study has not yet begun; results years away |
| Evidence Strength | 2 | Protocol only; no data |
Key Quantitative Result: None available.
External Validation: None; protocol stage.
Main Limitation: No results; single Italian center; feasibility study by design cannot demonstrate clinical utility.
Equity Implications: PRS applicability varies significantly by ancestry — most validated PRS were developed in European-ancestry populations, limiting utility for non-White women.
Evidence Maturity (confirmed): Exploratory.
Article 22 — DNA damage to systemic immunity — radio-immunotherapy review (PMID 42908903)
Study Design: Narrative review | Journal: Cell Insight | Triage Score: 3
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Synthesis of existing knowledge; no new data; single-author review |
| Clinical Relevance | 3 | Educational background value; no new clinical findings |
| Population Reach | 5 | Radio-immunotherapy is applied across many cancer types |
| Implementation Speed | 3 | Review only; no actionable new finding |
| Evidence Strength | 2 | Narrative review with no systematic methods; single author |
Key Quantitative Result: None.
External Validation: N/A.
Main Limitation: No new data; narrative structure; single-author; secondary journal.
Evidence Maturity (confirmed): Exploratory.